Worldwide experience with the TCI HeartMate system: issues and future perspective

Area of Science:

• Cardiology
• Medical Devices
• Biomedical Engineering

Background:

• The HeartMate left-ventricular assist system (LVAS) is a critical device for patients with advanced heart failure.
• Worldwide clinical application of the HeartMate LVAS began prior to 1997, involving numerous patients and centers.

Purpose of the Study:

• To summarize the cumulative clinical experience with the TCls HeartMate LVAS up to 1997.
• To report on the safety and efficacy of both the implantable pneumatic (IP) and vented electric (VE) versions of the HeartMate LVAS.

Main Methods:

• Analysis of data from 993 patients treated with HeartMate LVAS across 122 clinical centers worldwide.
• Categorization of patients based on the type of HeartMate LVAS used: HeartMate IP (753 patients) and HeartMate VE (240 patients).
• Assessment of patient outcomes, including transplant, explantation, duration of support, and device-related complications.

Main Results:

• A total of 993 patients received the HeartMate LVAS, with 753 on the IP version and 240 on the VE version.
• 59% of patients were either transplanted or had the pump removed after recovery, with an average support duration of 92 days.
• Device-related thromboembolic complications were low, ranging from 2-4%, even with minimal anticoagulation.
• 54 patients using the electric version were discharged home for up to 15 months, with some patients resuming work or school.

Conclusions:

• The HeartMate LVAS demonstrates a favorable safety profile with low rates of thromboembolic complications.
• The device facilitates patient recovery and transplant, with significant potential for improving quality of life and enabling return to daily activities.
• The cumulative data supports the HeartMate LVAS as a viable option for managing advanced heart failure.